Bipolar disorder treatment for Fort Lauderdale — the diagnosis primary care misses.

Fort Lauderdale patients from Las Olas, Victoria Park, and Coral Ridge drive 40 minutes north on I-95 for specialist-level bipolar care that primary care and general therapy typically miss. RECO Integrated Psychiatry runs lithium, lamotrigine, valproate, and second-generation antipsychotics with the full monitoring workflow built in, not deferred to labs down the street. Diagnosis is the load-bearing piece: MDQ, HCL-32, mood charting, and family collateral before pharmacology.

From Las Olas, Victoria Park, or Coral Ridge, RECO Integrated Psychiatry’s Delray Beach office sits 26 miles north on I-95 — a 40-minute drive most Fort Lauderdale adults fold into a workday for outpatient psychiatric care. For bipolar disorder specifically, the drive is worth it. This is the diagnosis primary care and general therapy most often miss, and the one where getting the pharmacology right changes the trajectory of a person’s decade.

Bipolar I, bipolar II, and bipolar spectrum

The diagnostic distinction is load-bearing. Bipolar I requires at least one manic episode — seven days of elevated or irritable mood with functional impairment, or any duration if hospitalization is required. Bipolar II requires a hypomanic episode plus a major depressive episode, without a full manic episode in the history. Bipolar spectrum — cyclothymia, bipolar NOS, subthreshold presentations, antidepressant-induced hypomania — captures the cyclical presentations that don’t fully meet criteria but still respond to bipolar-directed pharmacology.

Misdiagnosis of bipolar depression as unipolar drives most treatment failures in this population. A patient started on an SSRI for what looks like recurrent major depression often destabilizes — irritability, cycle acceleration, mixed features — because the underlying illness needs mood stabilizer cover before an antidepressant is safe. RECO’s evaluation uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), structured hypomania history from the patient and where possible a family member, and prospective mood charting rather than defaulting to the presenting complaint.

The distinction changes pharmacology directly. Bipolar I benefits from mood stabilizers plus second-generation antipsychotics. Bipolar II depression responds well to lamotrigine and quetiapine but not straightforwardly to lithium monotherapy. Bipolar spectrum presentations require careful antidepressant use with mood stabilizer cover — or, more often, no antidepressant at all.

Lithium: the medication we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with robust evidence for reducing suicide independent of mood response. It is also the medication clinicians most often avoid — not because the outcomes are worse, but because the monitoring feels burdensome and the therapeutic index is narrow.

RECO’s protocol is built to make the monitoring routine. Baseline labs include TSH, creatinine, BUN, calcium, CBC, and pregnancy testing where relevant. Target serum levels sit between 0.6 and 1.0 mEq/L for maintenance, drawn 12 hours post-dose. Levels run weekly during titration, then quarterly through the first year, then every six months once stable. Thyroid and renal function are checked twice yearly. Weight, blood pressure, and metabolic parameters are tracked at every visit.

For patients who tolerate lithium, the outcomes justify the effort. Response rates for classic euphoric mania and for long-term maintenance are the strongest in the pharmacopeia. Clients who were told lithium was “too much monitoring” by prior providers frequently do best on it once the workflow is in place.

Second-generation antipsychotics and where they fit

Every second-generation antipsychotic used in bipolar disorder has a defined FDA indication tied to phase of illness. Quetiapine is approved across bipolar depression, mania, and maintenance. Lurasidone is approved for bipolar depression and is often the first choice when metabolic burden is a concern. Aripiprazole covers mania and maintenance and adds well to lithium or valproate. Olanzapine and the olanzapine-fluoxetine combination treat bipolar depression and mania but carry the heaviest metabolic profile. Risperidone and cariprazine are indicated for mania, with cariprazine useful for bipolar depression at higher doses.

Choice is driven by phase, tolerability, and prior response — not by defaulting to whichever agent the last prescriber reached for. Metabolic parameters — weight, waist circumference, HbA1c, fasting lipids, blood pressure — are screened at baseline and followed at three, six, and twelve months in line with APA and ADA consensus guidelines. Akathisia, extrapyramidal effects, and prolactin elevation are assessed at every visit.

Combination therapy is common and appropriate. A patient stable on lithium plus quetiapine, or valproate plus aripiprazole, is not overmedicated — the maintenance evidence for combination therapy is stronger than for monotherapy in many presentations.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for bipolar II depression and for maintenance where depression is the predominant pole. Titration is deliberately slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — because rapid titration raises the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. Any rash during titration prompts immediate discontinuation and evaluation. Dosing interacts with valproate (halved) and with carbamazepine and oral contraceptives (roughly doubled).

Valproate treats acute mania and mixed episodes effectively and is often first-line where irritability, mixed features, or rapid cycling dominate. Monitoring covers LFTs, platelets, and serum levels targeting 50 to 125 mcg/mL. It is teratogenic and is not appropriate for patients of childbearing potential without a documented plan; the practice is explicit about this at prescription.

Carbamazepine and oxcarbazepine are second-line options with defined roles in mania and in patients who have not tolerated other agents. Each anticonvulsant has a specific monitoring protocol, and the practice runs all of them rather than referring out for medications that are inconvenient to manage.

What to expect on your first visit

The intake runs 60 to 75 minutes. It covers longitudinal mood history — first episode, cycling frequency, seasonality, past hypomania — along with substance use, medical comorbidities, current medications, family psychiatric history, and prior treatment response. Structured instruments include the MDQ or HCL-32, PHQ-9, GAD-7, and where indicated the ASRS for adult ADHD and the AUDIT for alcohol use, since comorbid ADHD and alcohol use disorder are common in bipolar disorder and both change the treatment plan.

Baseline labs are ordered at the first visit if not recent: TSH, CBC, CMP, HbA1c, lipid panel, and any medication-specific labs. A working diagnosis and an initial bipolar disorder treatment plan are documented before the visit ends. Most patients are seen at two-to-four week intervals during titration and monthly to quarterly once stable.

Insurance and admissions from Fort Lauderdale

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Verification of benefits is completed before the first appointment so out-of-pocket cost is known in writing. For Fort Lauderdale patients, the office is 26 miles north of Las Olas via I-95 — a 40-minute drive off-peak from Victoria Park, Coral Ridge, Rio Vista, or Wilton Manors. Telepsychiatry is offered for established patients whose clinical stability supports it, though initial evaluation and any lithium or antipsychotic initiation is done in person.

Serving residents of: Las Olas, Victoria Park, Coral Ridge, Rio Vista, Wilton Manors.